New Antibody-Drug combo targets Hard-to-Treat cancers

NCT ID NCT05797168

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This study tests a new drug called AZD5335, alone or with other cancer medicines, in people with advanced solid tumors like ovarian, lung, and endometrial cancers. The goal is to see if the drug is safe, tolerable, and shows signs of shrinking tumors. About 506 participants will take part in this early-phase trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Torvutatug samrotecan (AZD5335), an antibody-drug conjugate
What this could lead to: If successful, this could lead to a new treatment option for advanced ovarian, lung, and endometrial cancers.
What could go wrong: This is an early-phase trial (Phase 1/2a) focused on safety and dosing, so it is uncertain if the drug will be effective. Side effects may occur, and the trial is small.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma of Lung endometrial cancer endometrium neoplasm lung adenocarcinoma neoplasm ovarian cancer squamous cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIAL CANCER LUNG ADENOCARCINOMA LUNG SQUAMOUS CELL CARCINOMA OVARIAN CANCER

Contacts and locations

Locations

Research Site
RECRUITING

Duarte, California, 91010, United States
Research Site
RECRUITING

Irvine, California, 92618, United States
Research Site
WITHDRAWN

La Jolla, California, 92093, United States
Research Site
RECRUITING

Aurora, Colorado, 80045, United States
Research Site
TERMINATED

Louisville, Kentucky, 40202, United States
Research Site
RECRUITING

Boston, Massachusetts, 02114, United States
Research Site
RECRUITING

Detroit, Michigan, 48201, United States
Research Site
RECRUITING

Columbus, Ohio, 43201, United States
Research Site
RECRUITING

Portland, Oregon, 97239, United States
Research Site
RECRUITING

Providence, Rhode Island, 02903, United States
Research Site
WITHDRAWN

Providence, Rhode Island, 02905, United States
Research Site
RECRUITING

Houston, Texas, 77030, United States
Research Site
RECRUITING

Fairfax, Virginia, 22031, United States
Research Site
RECRUITING

Liverpool, 2170, Australia
Research Site
RECRUITING

Melbourne, 3000, Australia
Research Site
RECRUITING

Edmonton, Alberta, T6G 1Z2, Canada
Research Site
RECRUITING

London, Ontario, N6A 5W9, Canada
Research Site
RECRUITING

Toronto, Ontario, M5G 2M9, Canada
Research Site
RECRUITING

Montreal, Quebec, H2X 0A9, Canada
Research Site
RECRUITING

Montreal, Quebec, H4A 3J1, Canada
Research Site
RECRUITING

Chengdu, 610041, China
Research Site
RECRUITING

Chongqing, 400030, China
Research Site
RECRUITING

Guangzhou, 510000, China
Research Site
RECRUITING

Guangzhou, 510060, China
Research Site
RECRUITING

Jinan, 250117, China
Research Site
RECRUITING

Xi'an, 710061, China
Research Site
RECRUITING

Zhengzhou, 450008, China
Research Site
RECRUITING

Berlin, 13353, Germany
Research Site
NOT_YET_RECRUITING

Essen, 45136, Germany
Research Site
RECRUITING

Freiburg im Breisgau, 79106, Germany
Research Site
RECRUITING

Hanover, 30625, Germany
Research Site
RECRUITING

Leipzig, 04103, Germany
Research Site
RECRUITING

Mannheim, 68167, Germany
Research Site
RECRUITING

Regensburg, 93053, Germany
Research Site
RECRUITING

Haifa, 3109601, Israel
Research Site
RECRUITING

Ramat Gan, 52621, Israel
Research Site
RECRUITING

Hidaka-shi, 350-1298, Japan
Research Site
RECRUITING

Kashiwa, 227-8577, Japan
Research Site
RECRUITING

Kōtoku, 135-8550, Japan
Research Site
RECRUITING

Sunto-gun, 411-8777, Japan
Research Site
RECRUITING

Tokyo, 104-0045, Japan
Research Site
RECRUITING

Seoul, 03080, South Korea
Research Site
RECRUITING

Seoul, 06351, South Korea
Research Site
RECRUITING

Barcelona, 8035, Spain
Research Site
RECRUITING

Madrid, 28041, Spain
Research Site
RECRUITING

Madrid, 28050, Spain
Research Site
RECRUITING

Málaga, 29010, Spain
Research Site
RECRUITING

Taichung, 40705, Taiwan
Research Site
RECRUITING

Tainan, 70403, Taiwan
Research Site
RECRUITING

Taipei, 10002, Taiwan
Research Site
RECRUITING

Taipei, 11259, Taiwan
Research Site
RECRUITING

Ankara, 06050, Turkey (Türkiye)
Research Site
RECRUITING

Ankara, 06200, Turkey (Türkiye)
Research Site
RECRUITING

Ankara, 06800, Turkey (Türkiye)
Research Site
RECRUITING

Istanbul, 34718, Turkey (Türkiye)
Research Site
RECRUITING

Cambridge, CB2 0XY, United Kingdom
Research Site
RECRUITING

Glasgow, Scotland, G12 0YN, United Kingdom
Research Site
NOT_YET_RECRUITING

London, SE1 9RT, United Kingdom
Research Site
RECRUITING

London, SW3 6JJ, United Kingdom
Research Site
RECRUITING

Sutton, SM2 5PT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.